NoticeThis is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
Patients with a confirmation of advanced, high grade epithelial ovarian, fallopian tube or primary peritoneal cancer at surgery or at diagnostic biopsy and fulfilling the eligibility criteria to start a chemotherapy regimen in association with bevacizumab.
Tumor samples at surgery will be retrieved and evaluated for the HRD status by Myriad Mychoice CDxPlus test. After surgery patients will start a standard platinum-based chemotherapy plus bevacizumb. Patients who will be in complete or partial response after frontline platinum-based chemotherapy plus bevacizumab and with HRD-positive tumor according to the Myriad Mychoice CDx Plus evaluation (including BRCA1-2 mutated tumors) and fulfilling specific eligibility criteria, will start to take olaparib in addition to bevacizumab as maintenance therapy.
1 total trials
Filter these 1 trials by phase, country, sponsor and more.